BACKGROUND: The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed. METHODS: In phase 1 and pilot studies, the authors evaluated the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a 5-day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory AML. The cladribine dose was escalated as follows: 9.1, 13.6, 16.3, and 19.5 mg/m(2) per day (8.9 mg/m(2) per day in the pilot study). Outcome was analyzed according to the absence (Stratum 1) versus presence (Stratum 2) of previous allogeneic hematopoietic stem cell transplantation. Twenty-six patients (20 in Stratum 1 and 6 in Stratum 2) were treated. RESULTS: The MTD was not reached in Stratum 1, but a DLT occurred at the lowest cladribine dosage (9.1 mg/m(2) per day) in Stratum 2. Febrile neutropenia was common in both strata. Nine (34.6%) of 26 patients experienced a complete response, and 7 (30.4%) achieved a partial response; 5 (19.2%) were long-term survivors at the time of last follow-up. Clinical outcome was not associated with cladribine or topotecan systemic exposure. CONCLUSIONS: The combination was well tolerated in Sratum 1, and the response rate was encouraging. This regimen offers a postrecurrence treatment alternative for patients, especially those who have received anthracycline-containing chemotherapy. Copyright 2010 American Cancer Society.
BACKGROUND: The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed. METHODS: In phase 1 and pilot studies, the authors evaluated the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a 5-day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory AML. The cladribine dose was escalated as follows: 9.1, 13.6, 16.3, and 19.5 mg/m(2) per day (8.9 mg/m(2) per day in the pilot study). Outcome was analyzed according to the absence (Stratum 1) versus presence (Stratum 2) of previous allogeneic hematopoietic stem cell transplantation. Twenty-six patients (20 in Stratum 1 and 6 in Stratum 2) were treated. RESULTS: The MTD was not reached in Stratum 1, but a DLT occurred at the lowest cladribine dosage (9.1 mg/m(2) per day) in Stratum 2. Febrile neutropenia was common in both strata. Nine (34.6%) of 26 patients experienced a complete response, and 7 (30.4%) achieved a partial response; 5 (19.2%) were long-term survivors at the time of last follow-up. Clinical outcome was not associated with cladribine or topotecan systemic exposure. CONCLUSIONS: The combination was well tolerated in Sratum 1, and the response rate was encouraging. This regimen offers a postrecurrence treatment alternative for patients, especially those who have received anthracycline-containing chemotherapy. Copyright 2010 American Cancer Society.
Authors: Kristine R Crews; Varsha Gandhi; Deo Kumar Srivastava; Bassem I Razzouk; Xin Tong; Fred G Behm; William Plunkett; Susana C Raimondi; Ching-Hon Pui; Jeffrey E Rubnitz; Clinton F Stewart; Raul C Ribeiro Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: R A Krance; C A Hurwitz; D R Head; S C Raimondi; F G Behm; K R Crews; D K Srivastava; H Mahmoud; W M Roberts; X Tong; R L Blakley; R C Ribeiro Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: Beth Kurt; Patricia Flynn; Jerry L Shenep; Stanley Pounds; Shelly Lensing; Raul C Ribeiro; Ching-Hon Pui; Bassem I Razzouk; Jeffrey E Rubnitz Journal: Cancer Date: 2008-07-15 Impact factor: 6.860
Authors: Victor M Santana; William C Zamboni; Mark N Kirstein; Ming Tan; Tiebin Liu; Amar Gajjar; Peter J Houghton; Clinton F Stewart Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: Soheil Meshinchi; Wendy M Leisenring; Paul A Carpenter; Ann E Woolfrey; Eric L Sievers; Jerald P Radich; Jean E Sanders Journal: Biol Blood Marrow Transplant Date: 2003-11 Impact factor: 5.742
Authors: Robert J Wells; Mary T Adams; Todd A Alonzo; Robert J Arceci; Jonathan Buckley; Allen B Buxton; Kathryn Dusenbery; Alan Gamis; Margaret Masterson; Terry Vik; Phyllis Warkentin; James A Whitlock Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: Anna Birg Mitchell; Aksana Vasilyeva; Amar Gajjar; Victor M Santana; Clinton F Stewart Journal: Pediatr Blood Cancer Date: 2018-12-11 Impact factor: 3.167
Authors: Federica Saletta; Carol Wadham; David S Ziegler; Glenn M Marshall; Michelle Haber; Geoffrey McCowage; Murray D Norris; Jennifer A Byrne Journal: BBA Clin Date: 2014-06-28